JP2018508215A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508215A5 JP2018508215A5 JP2017546104A JP2017546104A JP2018508215A5 JP 2018508215 A5 JP2018508215 A5 JP 2018508215A5 JP 2017546104 A JP2017546104 A JP 2017546104A JP 2017546104 A JP2017546104 A JP 2017546104A JP 2018508215 A5 JP2018508215 A5 JP 2018508215A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- car
- domain
- item
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims description 41
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims description 35
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims description 22
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims description 22
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 18
- 230000005754 cellular signaling Effects 0.000 claims description 10
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 230000003834 intracellular effect Effects 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims description 7
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims description 5
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000006850 spacer group Chemical group 0.000 claims description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 4
- 150000007523 nucleic acids Chemical group 0.000 claims description 4
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims description 3
- 230000002463 transducing effect Effects 0.000 claims description 3
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 230000036210 malignancy Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201503742A GB201503742D0 (en) | 2015-03-05 | 2015-03-05 | Chimeric antigen receptor |
| GB1503742.7 | 2015-03-05 | ||
| PCT/GB2016/050574 WO2016139487A1 (en) | 2015-03-05 | 2016-03-04 | Chimeric antigen receptor (car) comprising a cd19-binding domain |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018508215A JP2018508215A (ja) | 2018-03-29 |
| JP2018508215A5 true JP2018508215A5 (enExample) | 2019-03-07 |
| JP6574848B2 JP6574848B2 (ja) | 2019-09-11 |
Family
ID=52998440
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017546104A Active JP6574848B2 (ja) | 2015-03-05 | 2016-03-04 | Ｃｄ１９結合ドメインを含むキメラ抗原レセプター（ｃａｒ） |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US10457730B2 (enExample) |
| EP (1) | EP3265490B1 (enExample) |
| JP (1) | JP6574848B2 (enExample) |
| CN (1) | CN107406517B (enExample) |
| AU (1) | AU2016227498B2 (enExample) |
| CA (1) | CA2978381C (enExample) |
| DK (1) | DK3265490T3 (enExample) |
| ES (1) | ES2732067T3 (enExample) |
| FR (1) | FR25C1040I1 (enExample) |
| GB (1) | GB201503742D0 (enExample) |
| HU (2) | HUE044298T2 (enExample) |
| PL (1) | PL3265490T3 (enExample) |
| PT (1) | PT3265490T (enExample) |
| TR (1) | TR201909647T4 (enExample) |
| WO (1) | WO2016139487A1 (enExample) |
Families Citing this family (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201608393TA (en) | 2014-04-10 | 2016-11-29 | Seattle Children S Hospital Dba Seattle Children S Res Inst | Transgene genetic tags and methods of use |
| EP3143134B1 (en) | 2014-05-15 | 2020-10-28 | National University of Singapore | Modified natural killer cells and uses thereof |
| HRP20240357T1 (hr) | 2014-12-24 | 2024-06-07 | Autolus Limited | Stanica |
| GB201503742D0 (en) * | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| US11458167B2 (en) | 2015-08-07 | 2022-10-04 | Seattle Children's Hospital | Bispecific CAR T-cells for solid tumor targeting |
| US9681109B2 (en) * | 2015-08-20 | 2017-06-13 | Qualcomm Incorporated | Systems and methods for configurable demodulation |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| SG11201908492PA (en) * | 2017-03-27 | 2019-10-30 | Nat Univ Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
| EP3601537A4 (en) | 2017-03-27 | 2021-01-13 | National University of Singapore | STIMULATING CELL LINES FOR EX VIVO EXPANSION AND ACTIVATION OF NATURAL KILLER CELLS |
| CN107098981B (zh) * | 2017-06-29 | 2020-05-01 | 青岛麦迪赛斯医疗技术有限公司 | 一种靶向cd19的嵌合抗原受体修饰的t淋巴细胞 |
| EP3662055A1 (en) * | 2017-08-02 | 2020-06-10 | Autolus Limited | Cells expressing a chimeric antigen receptor or engineered tcr and comprising a nucleotide sequence which is selectively expressed |
| CA3083936C (en) * | 2017-12-06 | 2022-08-23 | Abclon Inc. | Anti-cd19 antibody or antigen-binding fragment and cd19-specific chimeric antigen receptor comprising the same |
| CN107903326B (zh) * | 2018-01-02 | 2020-06-30 | 广东省人民医院(广东省医学科学院) | 包含C3aR胞内结构域的嵌合抗原受体、慢病毒载体、表达细胞及药物 |
| CN108047332B (zh) * | 2018-01-15 | 2021-08-24 | 阿思科力(苏州)生物科技有限公司 | 以cd19为靶点的特异性抗体、car-nk细胞及其制备和应用 |
| CN111801348A (zh) | 2018-02-09 | 2020-10-20 | 新加坡国立大学 | 活化性嵌合受体及其在自然杀伤细胞免疫疗法中的用途 |
| CN111094358A (zh) * | 2018-02-11 | 2020-05-01 | 江苏恒瑞医药股份有限公司 | 一种分离的嵌合抗原受体以及包含其的修饰t细胞及用途 |
| KR20200138741A (ko) | 2018-04-02 | 2020-12-10 | 내셔널 유니버시티 오브 싱가포르 | 면역 세포에서 발현되는 막-결합 항-사이토카인 비-신호전달 결합제를 이용한 인간 사이토카인의 중화 |
| CN116836297A (zh) * | 2018-04-12 | 2023-10-03 | 上海赛比曼生物科技有限公司 | 靶向bcma的嵌合抗原受体及其制法和应用 |
| AU2019269118B2 (en) | 2018-05-15 | 2025-02-27 | Autolus Limited | Chimeric antigen receptor |
| GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
| CN108794642A (zh) * | 2018-07-05 | 2018-11-13 | 宁波安诺柏德生物医药科技有限公司 | 一种嵌合抗原细胞受体及其应用 |
| CN110819678A (zh) * | 2018-08-07 | 2020-02-21 | 上海恒润达生生物科技有限公司 | 一种评估cart细胞有效性的方法 |
| CN110850068B (zh) * | 2018-08-21 | 2023-08-15 | 上海恒润达生生物科技股份有限公司 | 一种嵌合抗原受体亲和力检测方法 |
| JP7560882B2 (ja) | 2018-08-29 | 2024-10-03 | ナショナル ユニヴァーシティー オブ シンガポール | 遺伝子修飾免疫細胞の生存及び増加を特異的に刺激するための方法 |
| EP3856775B9 (en) * | 2018-09-27 | 2025-01-22 | Autolus Limited | Chimeric antigen receptor |
| GB201816522D0 (en) | 2018-10-10 | 2018-11-28 | Autolus Ltd | Methods and reagents for analysing nucleic acids from single cells |
| EP3873540A4 (en) | 2018-10-31 | 2022-07-27 | Mayo Foundation for Medical Education and Research | METHODS AND MATERIALS FOR THE TREATMENT OF CANCER |
| WO2020092839A1 (en) | 2018-10-31 | 2020-05-07 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| CN109468282B (zh) * | 2018-11-22 | 2019-06-18 | 青岛协和华美医学诊断技术有限公司 | 一种靶向cd19的嵌合抗原受体t细胞的制备方法及应用 |
| CN109734813B (zh) * | 2019-01-28 | 2022-06-17 | 广东昭泰体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
| EP3912992A4 (en) * | 2019-02-04 | 2022-11-23 | National University Corporation Ehime University | Car library and production method for scfv |
| US12419913B2 (en) | 2019-02-08 | 2025-09-23 | Dna Twopointo, Inc. | Modification of CAR-T cells |
| CN113795513B (zh) | 2019-02-13 | 2025-02-18 | 布里格姆妇女医院 | 抗外周淋巴结地址素抗体及其用途 |
| EP3773918A4 (en) | 2019-03-05 | 2022-01-05 | Nkarta, Inc. | ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY |
| GB201903237D0 (en) | 2019-03-08 | 2019-04-24 | Autolus Ltd | Method |
| CN113543792A (zh) * | 2019-03-08 | 2021-10-22 | 奥托路斯有限公司 | 包含工程化嵌合抗原受体和car调节剂的组合物和方法 |
| US20220233593A1 (en) * | 2019-06-04 | 2022-07-28 | Nkarta, Inc. | Combinations of engineered natural killer cells and engineered t cells for immunotherapy |
| US20220257796A1 (en) | 2019-07-02 | 2022-08-18 | Fred Hutchinson Cancer Research Center | Recombinant ad35 vectors and related gene therapy improvements |
| CA3146987A1 (en) * | 2019-07-17 | 2021-01-21 | National University Of Singapore | Functional binders synthesized and secreted by immune cells |
| JP7723420B2 (ja) * | 2019-08-28 | 2025-08-14 | キングス・カレッジ・ロンドン | Ｂ細胞標的化並列ＣＡＲ（ｐＣＡＲ）治療的薬剤 |
| US20230028399A1 (en) * | 2020-01-13 | 2023-01-26 | Nkarta, Inc. | Bcma-directed cellular immunotherapy compositions and methods |
| MX2022010936A (es) | 2020-03-05 | 2022-11-16 | Neotx Therapeutics Ltd | ³métodos y composiciones para el tratamiento del cáncer con células inmunológicas. |
| CN113402612A (zh) * | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
| JP2023525049A (ja) * | 2020-05-08 | 2023-06-14 | シアトル・チルドレンズ・ホスピタル・ドゥーイング／ビジネス／アズ・シアトル・チルドレンズ・リサーチ・インスティテュート | ナチュラルキラー細胞を標的とするキメラ抗原受容体（ｃａｒ） |
| US20220031751A1 (en) | 2020-08-03 | 2022-02-03 | Kyverna Therapeutics, Inc. | Methods of producing t regulatory cells, methods of transducing t cells, and uses of the same |
| US20230366893A1 (en) * | 2020-09-29 | 2023-11-16 | Washington University | Methods to determine risk of neurotoxicity |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| TW202242117A (zh) | 2020-12-30 | 2022-11-01 | 美商亞勞諾斯醫療公司 | 包含多順反子表現卡匣之重組載體及其使用方法 |
| WO2022165419A1 (en) | 2021-02-01 | 2022-08-04 | Kyverna Therapeutics, Inc. | Methods for increasing t-cell function |
| WO2022214089A1 (zh) * | 2021-04-08 | 2022-10-13 | 克莱格医学有限公司 | 细胞免疫治疗的应用 |
| CN117088975B (zh) * | 2022-05-11 | 2024-06-25 | 东莞市朋志生物科技有限公司 | 抗白蛋白抗体、检测白蛋白的试剂和试剂盒 |
| JP2025516531A (ja) | 2022-05-11 | 2025-05-30 | オートラス リミテッド | 高リスクまたは再発性小児急性リンパ芽球性白血病のｃｄ１９／２２ ｃａｒ ｔ細胞処置 |
| CN116253794B (zh) * | 2022-08-19 | 2025-04-04 | 首都医科大学宣武医院 | 一种用于car-t细胞调控的抗体及其应用 |
| KR20250131823A (ko) | 2023-03-31 | 2025-09-03 | 아벨제타 인크. | Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체 |
| WO2024246526A1 (en) | 2023-05-30 | 2024-12-05 | Autolus Limited | Cd19car t-cell treatment of relapsed/refractory b-cell acute lymphoblastic leukaemia |
| WO2025008642A1 (en) | 2023-07-05 | 2025-01-09 | Autolus Limited | Method |
| CN119350497A (zh) * | 2023-07-24 | 2025-01-24 | 星尘生物科技(上海)有限公司 | 人源化抗cd19单链可变区片段及其用途 |
| GB202316184D0 (en) | 2023-10-23 | 2023-12-06 | Autolus Ltd | Method |
| WO2025088308A1 (en) | 2023-10-23 | 2025-05-01 | Autolus Limited | Products and methods for treating autoimmune diseases |
| EP4574838A1 (en) | 2023-12-21 | 2025-06-25 | Vilnius University | Chimeric antigen receptor (car) with enhanced recruitment of signaling partners |
| GB202403564D0 (en) | 2024-03-12 | 2024-04-24 | Autolus Ltd | Method |
| WO2025215360A1 (en) | 2024-04-09 | 2025-10-16 | Autolus Limited | Method |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010095031A2 (en) | 2009-02-23 | 2010-08-26 | Glenmark Pharmaceuticals S.A. | Humanized antibodies that bind to cd19 and their uses |
| CA2863799C (en) | 2012-02-22 | 2020-09-01 | Matthew J. FRIGAULT | Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer |
| RS65484B1 (sr) * | 2013-05-13 | 2024-05-31 | Cellectis | Cd19 specifični himerni antigenski receptor i njegove primene |
| HRP20240357T1 (hr) | 2014-12-24 | 2024-06-07 | Autolus Limited | Stanica |
| GB201503742D0 (en) * | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
-
2015
- 2015-03-05 GB GB201503742A patent/GB201503742D0/en not_active Ceased
-
2016
- 2016-03-04 EP EP16709529.8A patent/EP3265490B1/en active Active
- 2016-03-04 US US15/555,508 patent/US10457730B2/en active Active
- 2016-03-04 CA CA2978381A patent/CA2978381C/en active Active
- 2016-03-04 DK DK16709529.8T patent/DK3265490T3/da active
- 2016-03-04 JP JP2017546104A patent/JP6574848B2/ja active Active
- 2016-03-04 WO PCT/GB2016/050574 patent/WO2016139487A1/en not_active Ceased
- 2016-03-04 TR TR2019/09647T patent/TR201909647T4/tr unknown
- 2016-03-04 PL PL16709529T patent/PL3265490T3/pl unknown
- 2016-03-04 ES ES16709529T patent/ES2732067T3/es active Active
- 2016-03-04 AU AU2016227498A patent/AU2016227498B2/en active Active
- 2016-03-04 HU HUE16709529 patent/HUE044298T2/hu unknown
- 2016-03-04 CN CN201680013844.7A patent/CN107406517B/zh active Active
- 2016-03-04 PT PT16709529T patent/PT3265490T/pt unknown
-
2019
- 2019-09-17 US US16/573,854 patent/US11578126B2/en active Active
-
2023
- 2023-01-12 US US18/153,990 patent/US20230220077A1/en active Pending
-
2025
- 2025-09-08 HU HUS2500036C patent/HUS2500036I1/hu unknown
- 2025-10-03 FR FR25C1040C patent/FR25C1040I1/fr active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018508215A5 (enExample) | ||
| KR102483822B1 (ko) | 태그된 키메라 이펙터 분자 및 그의 리셉터 | |
| JP2017508466A5 (enExample) | ||
| JP7573441B2 (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| CN112390892B (zh) | 一种嵌合抗原受体以及表达该嵌抗原受体的免疫效应细胞 | |
| JP2018527919A5 (enExample) | ||
| JP2019532625A5 (enExample) | ||
| JP2017500869A5 (enExample) | ||
| KR20190116420A (ko) | Bcma 관련 암 및 자가면역 장애의 치료를 위한 조합 요법 | |
| JP2020530989A5 (enExample) | ||
| JP2015527070A5 (enExample) | ||
| JP2016520074A5 (enExample) | ||
| RU2019105693A (ru) | Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага | |
| RU2017134652A (ru) | Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) k cd19 | |
| JP2019530431A5 (enExample) | ||
| JP2018528776A5 (enExample) | ||
| JP2019535262A5 (enExample) | ||
| CN112638947A (zh) | 用于治疗实体瘤的嵌合抗原受体细胞 | |
| US20250236864A1 (en) | CAR LIBRARY AND scFv MANUFACTURING METHOD | |
| CN118843693A (zh) | 靶向bcma的嵌合抗原受体及其应用 | |
| AU2021308745A1 (en) | Multispecific chimeric antigen receptors and uses thereof | |
| KR20200041377A (ko) | Strep-tag 특이적 결합 단백질 및 그 용도 | |
| JP2022530541A (ja) | Ｂｃｍａを標的とするｃａｒ ｔ細胞及びその使用 | |
| EP4007777B1 (en) | Car t-cells against bcma for the treatment of multiple myeloma | |
| WO2024017362A1 (zh) | 靶向gprc5d和/或bcma的嵌合抗原受体及其应用 |